• Orthocell tendon treatment Ortho-ATITM to be presented at leading Australian health conferences
• Conferences being attended by top orthopaedic and sports medicine researchers and doctors
• Regenerative medicine experts to discuss positive trial results
Perth, Australia; 15 October 2014: Regenerative medicine company Orthocell Limited is pleased to announce the outcomes of trials of its world-leading tendon regeneration therapy will be presented at two key Australian health conferences this week.
Orthocell’s clinical trial results for its Ortho-ATITM treatment for degenerate tendon injuries of the elbow and hip, will be presented at the Australian Orthopaedic Association’s annual scientific meeting in Melbourne and Sports Medicine Australia’s Be Active conference in Canberra.
The presentations at both conferences will also address the results of studies conducted for patients with hip tendon pain, called gluteal tendinopathy, and elbow tendon injuries known as tennis elbow. The gluteal study found Ortho-ATI™ demonstrated significant clinical improvement for recalcitrant gluteal tendinopathy to 12 months and maintained this improvement out to 24 months whilst the elbow study has demonstrated durable long term repair that lasts out to five years after treatment.
“Presenting at these two prestigious conferences, where Australia’s leading musculoskeletal researchers and doctors will be attending, is a great opportunity for us to show how our treatment is helping patients with chronic tendon pain and once again validates our scientific excellence and clinical relevance,” Orthocell Managing Director Paul Anderson said.
Orthocell’s Chief Scientific Officer Professor Ming-Hao Zheng, will be presenting at both conferences along with Consultant orthopaedic surgeon Dr Tom Bucher and UWA Assistant Professor Dr. Jay Ebert.
Earlier this year Orthocell released the results of a long-term clinical study into its Ortho-ATITM treatment for a severe form of tennis elbow that showed grip strength scores improved by an average 84% at one year after treatment and 207% at an average of 4.5 years after undergoing treatment (refer ASX announcement 25 August 2014).
For more information, please contact:
General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au
Media enquiries
Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au
Investor Relations
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au
About Orthocell Limited
Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approval.
Help employers find you! Check out all the jobs and post your resume.
• Conferences being attended by top orthopaedic and sports medicine researchers and doctors
• Regenerative medicine experts to discuss positive trial results
Perth, Australia; 15 October 2014: Regenerative medicine company Orthocell Limited is pleased to announce the outcomes of trials of its world-leading tendon regeneration therapy will be presented at two key Australian health conferences this week.
Orthocell’s clinical trial results for its Ortho-ATITM treatment for degenerate tendon injuries of the elbow and hip, will be presented at the Australian Orthopaedic Association’s annual scientific meeting in Melbourne and Sports Medicine Australia’s Be Active conference in Canberra.
The presentations at both conferences will also address the results of studies conducted for patients with hip tendon pain, called gluteal tendinopathy, and elbow tendon injuries known as tennis elbow. The gluteal study found Ortho-ATI™ demonstrated significant clinical improvement for recalcitrant gluteal tendinopathy to 12 months and maintained this improvement out to 24 months whilst the elbow study has demonstrated durable long term repair that lasts out to five years after treatment.
“Presenting at these two prestigious conferences, where Australia’s leading musculoskeletal researchers and doctors will be attending, is a great opportunity for us to show how our treatment is helping patients with chronic tendon pain and once again validates our scientific excellence and clinical relevance,” Orthocell Managing Director Paul Anderson said.
Orthocell’s Chief Scientific Officer Professor Ming-Hao Zheng, will be presenting at both conferences along with Consultant orthopaedic surgeon Dr Tom Bucher and UWA Assistant Professor Dr. Jay Ebert.
Earlier this year Orthocell released the results of a long-term clinical study into its Ortho-ATITM treatment for a severe form of tennis elbow that showed grip strength scores improved by an average 84% at one year after treatment and 207% at an average of 4.5 years after undergoing treatment (refer ASX announcement 25 August 2014).
For more information, please contact:
General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au
Media enquiries
Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au
Investor Relations
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au
About Orthocell Limited
Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approval.
Help employers find you! Check out all the jobs and post your resume.
